Eikon Therapeutics Inc (EIKN)

$EIKN 🙃✨️

$EIKN is this up on moderna news ?

$EIKN any news?

$EIKN booking my punta cana trip now

$EIKN— Why ESMO Could Be a Major Pipeline Re-Rating Event Eikon’s 7 ESMO abstracts matter less for quantity than for quality: several datasets now reflect more biologically selected, expanded cohorts, which may improve efficacy versus earlier readouts. ──────── EIK1001 — 1L NSCLC (Oct 26 | Primary Value Driver) ASCO Baseline Data • Pooled ORR: 63.1% • DCR: 90.8% • Squamous cohort: 72.4% ORR / 100% DCR • Median follow-up: 8.8 months (squamous) • Non-squamous DOR: >11 months (early signal) ESMO Focus • Durability of 72.4% squamous ORR • Conversion of response into PFS / DOR maturity • Squamous vs non-squamous separation • Evidence of response deepening or plateauing Why It Matters • Lead asset and largest rNPV contributor • Oct 26 is the key catalyst • Durability confirmation could materially shift PoS assumptions ──────── EIK1003 — Selective PARP1 Inhibitor Monotherapy / Breast Cancer ASCO Baseline Data • ORR: 14.3% • PARPi-naïve subgroup: 26.7% ORR ESMO Focus • Validation of 25–30%+ ORR in enriched PARPi-naïve cohorts • Dose response (20 mg vs 60 mg) • Consistency in HER2-negative breast cancer Why It Matters • Highlights importance of biological enrichment • Mixed-population ORR likely understates true activity • Could reposition drug as subgroup-selective high-activity therapy ──────── EIK1003 + Paclitaxel (Ovarian / Combination) ASCO Baseline Data • ORR: 24.5% • Platinum-resistant ovarian cancer: 29.6% ORR • Prior taxane exposure: 92% of responders ESMO Focus • Cohort 1D (platinum + paclitaxel) • Maintenance of ~25–30% ORR range • Combination safety profile Why It Matters • Tests PARP1 selectivity under chemo pressure • If maintained, supports chemo-stackability • Expands ovarian franchise potential ──────── EIK1003 — Prostate (Oct 23 Readout) ESMO Focus • PSA50 response rate • Early RECIST activity • PSA durability Why It Matters • First expansion beyond breast/ovarian • Validates multi-franchise potential • Expands peak TAM optionality ──────── EIK1004 — CNS-Penetrant PARP1 (Oct 23) ESMO Focus • CNS penetration / PK profile • Safety and tolerability • Intracranial or CNS tumor activity Why It Matters • Rare CNS-active PARP-class asset • Positive signal opens neuro-oncology expansion • High optionality despite early stage ──────── EIK1005 — WRN Inhibitor (Oct 23) ESMO Focus • Dose escalation and safety • PK/PD validation in MSI-H/dMMR tumors • Early biomarker signals Why It Matters • Expands into synthetic lethality beyond PARP • Platform validation stage • Not yet efficacy-driven ──────── ESMO Catalyst Timeline Oct 23 — Platform Expansion (Medium Impact Overall) • EIK1003 (Prostate Combo) → Medium impact • PSA50, early response signals • First non-breast/ovarian validation • EIK1004 (CNS PARP1) → Medium–High (if CNS signal emerges) • Brain penetration, intracranial activity • Potential CNS oncology entry • EIK1005 (WRN) → Low–Medium impact • Safety, PK, early PD markers • Platform expansion signal ──────── Oct 26 — Core Value Driver (High Impact) • EIK1001 (1L NSCLC expansion) → VERY HIGH impact • Squamous durability (72.4% ORR sustainability) • DOR/PFS maturation • Cohort consistency Why It Matters • Primary rNPV driver • Most important near-term catalyst • Durability confirmation could re-rate probability assumptions ──────── Valuation Framework (Scenario-Based) • Base pipeline rNPV: ~$2.5B • Constructive ESMO: ~$2.4–2.8B implied value • Bull case (multi-asset validation): ~$4–5B implied value Not price targets—scenario outputs. ──────── Balance Sheet Context • Cash & marketable securities: $531.2M • Q2 R&D: $75.5M • Net loss: $88.4M • Runway: into 2H 2027 ──────── Key Takeaway ESMO does not require universal success across programs. The key sensitivities are: • EIK1001 durability (NSCLC squamous cohort) • EIK1003 validation in PARPi-naïve enriched populations If both hold, the market may begin assigning independent high-confidence probabilities across multiple assets, a typical trigger for pipeline re-rating. Core insight: the datasets are not just larger — they are more biologically selected, creating asymmetric upside potential. NFA/DYOD (Not Financial Advice/Do Your Own Due Diligence ).

$MRK Why nobody is talking about $EIKN ? It is seen as merck 2.0… eik1001 could be a big game changer.

$EIKN - Q2: Funded Into Major 7-Abstract ESMO Catalyst Eikon finished Q2 with $531.2M cash and runway into 2H27. No debt or preferred stock, although ~$252M of $313M liabilities are operating leases, so it’s not a pure net-cash story. The bigger story is ESMO 2026, where Eikon has seven accepted abstracts spanning four clinical assets: 2 EIK1001, 2 EIK1003, 1 EIK1004 and 2 EIK1005. That breadth matters. This isn’t simply another update on the lead EIK1001 program. ESMO provides multiple opportunities to establish value across the pipeline: * EIK1003: updated monotherapy/paclitaxel data plus the first abiraterone combination data in metastatic prostate cancer. * EIK1004: first-in-human data for the CNS-penetrant PARP1 inhibitor. * EIK1005: initial clinical safety/tolerability/PK data for Eikon’s internally developed WRN inhibitor, plus its Phase 1/2 monotherapy/KEYTRUDA program. * EIK1001: updated TeLuRide-005 NSCLC results plus TeLuRide-008 registrational-program presentation. The implication: seven abstracts across four drugs gives Eikon multiple shots on goal. Strong data from EIK1003/1004/1005 could begin shifting the valuation from primarily EIK1001 toward a multi-asset oncology platform, while weak early data could challenge that pipeline-premium thesis. That makes Oct. 23 particularly important: multiple datasets, including first clinical looks at previously unproven assets, can start answering whether Eikon has genuine pipeline breadth rather than one lead program plus optionality. Q2 shows they have the cash to get there. ESMO starts showing what the pipeline may actually be worth. NFAD/DYOR.

$EIKN I think I smell news idk I feel it

$EIKN 🙃✨️

$EIKN $ZURA $PLAG 👁